Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 05, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
I-Med Pharma USA Partners With DryEye Rescue to Distribute Its Innovative Dry Eye Product Portfolio in the United States
February 03, 2022 11:00 ET
|
I-MED Pharma
MONTREAL, Feb. 03, 2022 (GLOBE NEWSWIRE) -- With the recent launch of its line of dry eye diagnostics, management, and treatment solutions into the United States, I-MED Pharma USA has partnered with...
NTC and I-MED Pharma form strategic partnership to bring the leading HA-based dry eye ointment to the United States market
December 15, 2021 07:00 ET
|
I-MED Pharma
MONTREAL, Dec. 15, 2021 (GLOBE NEWSWIRE) -- NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, and I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and...
I-MED Pharma USA Announces Michelle Schnabel as VP Business Development
November 09, 2021 11:00 ET
|
I-MED Pharma
MONTREAL, Nov. 09, 2021 (GLOBE NEWSWIRE) -- With the recent expansion into the United States, I-MED Pharma USA is proud to announce the appointment of Michelle Schnabel to the role of VP Business...
I-MED Pharma USA Announces Brent Jones as Chief Commercial Officer
November 08, 2021 11:00 ET
|
I-MED Pharma
MONTREAL, Nov. 08, 2021 (GLOBE NEWSWIRE) -- With the recent expansion into the United States, I-MED Pharma USA is proud to announce the appointment of Brent Jones to Chief Commercial Officer...
I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.
November 05, 2021 11:00 ET
|
I-MED Pharma
MONTREAL, Nov. 05, 2021 (GLOBE NEWSWIRE) -- I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market. Their uniquely formulated line of ocular surface...
I-MED Pharma launches tearcheck® in Canada - A new standard in dry eye analysis
November 10, 2020 10:20 ET
|
I-MED Pharma
MONTREAL, Nov. 10, 2020 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, announces the launch of tearcheck®, a new Health Canada approved...
Patented IRPL® Technology Now Available in Canada!
April 27, 2020 10:48 ET
|
I-MED Pharma
MONTREAL, April 27, 2020 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is proud to announce Health Canada approval for the E>Eye...
I-MED Pharma to Launch Its Most Advanced Artificial Tear to Date With I-DROP® MGD
February 03, 2020 14:11 ET
|
I-MED Pharma
MONTREAL, Feb. 03, 2020 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, announced today that the company has plans to launch its newest,...
I-MED Pharma Celebrates 30 Years of Providing OSD & Surgical Solutions to the Global Eye Care Community
April 01, 2019 10:22 ET
|
I-MED Pharma
MONTREAL, April 01, 2019 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, proudly announces its 30-year anniversary providing OSD &...